

QIBA Nuclear Medicine Update Call
FDG-PET/CT, Amyloid, and SPECT BCs combined

26 June 2015 at 9 AM CT

DRAFT Call Summary

In attendance:

RSNA

<i>Eric Perlman, MD - Moderator (Co-chair, Amyloid BC)</i>	Janice Campbell, PhD	Daniel Sullivan, MD	Joe Koudelik
<i>Anne Smith, PhD (Co-chair, Amyloid BC)</i>	Patricia Cole, PhD, MD	Akiko Suzuki, MD, PhD	Julie Lisiecki
<i>Rathan Subramaniam, MD, PhD (Co-chair, FDG-PET BC)</i>	John Dickson, PhD	Pierre Tervé, MS	
<i>John Sunderland, PhD (Co-chair, FDG-PET BC)</i>	Howard Higley, PhD	Huseyin Toré, MD	
<i>Scott Wollenweber, PhD (Co-chair, FDG-PET BC)</i>	Gil Kovalski, PhD	John Wolodzko, PhD	
<i>Yuni Dewaraja, PhD (Co-chair, SPECT BC)</i>	Martin Lodge, PhD	Jeffrey Yap, PhD	
<i>P. David Mozley, MD (Co-chair, SPECT BC)</i>	Annette Schmid, PhD	Brian Zimmerman, PhD	

NIBIB RFP Update

- A response to the NIBIB RFP for 2015 – 2016 is due by July 15th; QIBA leadership is working on the proposal document now
- The QIBA Steering Committee is also in the process of ranking final projects for inclusion within the RFP

Biomarker Committee Updates

- Dr. Turkington and the Round-3/4 feasibility test (Profile checklist) team are working to vet 19 items for the next revision of the FDG-PET Profile
- Manufacturers will be engaged next to review the conformance checklist for a real-world perspective
- Dr. Kinahan is leading a publication effort for the latest Profile document; Lean Body Mass (LBM) to be determined
- Dr. Subramaniam is collecting raw data from papers reviewed to perform a meta-analysis; approximately 10 authors must be queried to see if they will share data
- The Amyloid BC distributed its first Profile draft for internal review and comment on June 16th.
- Committee members are asked to use a dedicated Excel spreadsheet for comments
 - Comments are welcome to the co-chairs: Dr. Perlman (esperlman@gmail.com); Dr. Smith (Anne.M.Smith@siemens.com); or Dr. Minoshima (sminoshima@hsc.utah.edu).
- Dr. Sunderland is awaiting segmentation (data) results to begin machining the physical amyloid phantom
- SPECT has been approved as a Biomarker Committee and its co-chairs are:
 - Dr. Dewaraja (University of Michigan)
 - Dr. Mozley (Endocyte, Inc.)
 - Dr. Seibyl (Yale / Institute for Neurodegenerative Disorders)
- DaTscan will be the starting point for a Profile document
- The co-chairs will work with RSNA staff to schedule groundwork task force calls, some of which may use the NM 9 am CT time slot on Fridays, if available via the group rotation schedule

Scheduling / Planning

- Dr. Perlman reminded all group leaders to provide agenda topics in order to best utilize call time

Proposed Nuclear Medicine Calls (Fridays, 9 am CT):

- | | |
|--|---|
| <ul style="list-style-type: none">• July 3: No call. RSNA Offices Closed.• July 10: FDG-PET Biomarker Ctte• July 17: Amyloid Biomarker Ctte• July 24: SPECT Biomarker Ctte• July 31: Combined NM Biomarker Committees | <ul style="list-style-type: none">• August 7: FDG-PET BC• August 14: Amyloid BC• August 21: SPECT BC• August 28: Combined NM BCs |
|--|---|